Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that exosomes and secretome derived from rat hair follicle stem cells show promising potential for wound healing and tissue repair, demonstrating significant wound closure and suggesting their broader applicability in regenerative medicine.

This review suggests that immunomodulators, including TNF-α blockers and IL inhibitors, may improve symptoms of moderate-to-severe dissecting cellulitis of the scalp, but their effects on hair regrowth and scarring remain unclear.

This study observed that, among alopecia areata patients in Fujian, China, lower IgG4 levels and higher IFN-γ levels were statistically significant, suggesting their potential role as biomarkers for the condition and highlighting avenues for future therapeutic developments.

γδT cells can protect hair follicles from alopecia areata and promote hair regrowth.

This study found that γδTregs can prevent and treat alopecia areata in a mouse model with human scalp transplants, suggesting potential for cell-based therapies in autoimmune diseases like alopecia.

This study found that patients with alopecia areata had increased levels of serum immunoglobulin E and interleukin-13 compared to healthy controls, with additional variation in levels observed across age and weight.

This source concludes that repurposing existing drugs, such as using metformin with other treatments in advanced non-small cell lung cancer, may enhance cancer patient outcomes, although various technical and legal challenges need addressing.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.

This study found that patients with alopecia areata had significantly higher levels of circulating DNA for certain cytokines compared to healthy controls, suggesting that increased circulating DNA may be linked to hair follicle damage in these patients.

This study reviewed the historical and current uses of frankincense, highlighting its potential antiviral, anti-inflammatory, and immunomodulatory effects, particularly noting some clinical evidence that suggests its use in treating COVID-19 symptoms, although more data is needed.

This study identified Th22 cells as key effectors in hair regeneration driven by thymosin beta 15, suggesting they could be potential targets for hair regrowth therapies.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

In this study, treatment with IL-2C to expand Tregs effectively halted hair loss progression in a murine model of alopecia areata.

This article reviews the pathogenesis, complications, and management of lichen planus, especially its persistent oral form, and highlights the need for further prospective studies.

This study found that co-administering sasam-Kyeongokgo with gefitinib enhanced gefitinib's anti-tumor activity and exhibited favorable anti-cachexia effects in mice with non-small-cell lung cancer.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

The authors propose that higher testosterone levels in hospitalized COVID-19 patients might be associated with worse outcomes.

This study found that serum IL-17A levels were significantly higher in patients with alopecia areata compared to healthy controls and correlated with disease severity and activity.

This review discusses the potential of ginseng and its metabolites for treating hair loss and reports no new clinical findings.

This review discusses potential biomarkers for alopecia and their significance, and while it highlights areas for future research, it reports no new clinical results.

This paper discusses two preclinical models for studying alopecia areata and finds that testing new therapeutic agents should involve both the C3H/HeJ mouse model and the humanized mouse model for comprehensive insights.

This study found that plasmacytoid dendritic cells may initiate alopecia areata in mice by overexpressing interferon-alpha.

This review discusses recent genome-wide association studies identifying novel candidate genes for various forms of alopecia, providing insights into their pathogenesis and molecular mechanisms, but reports no new clinical results.

Higher levels of certain nerve-related proteins are linked to hair loss in women with scalp pain.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.